ubidecarenone prodrugs (Receptagen)

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug Nameubidecarenone prodrugs (Receptagen)
Drug Alias NameCoQ10 platform technology (Receptagen)coenzyme Q10 prodrugs (Receptagen)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNeuroprotectantsApoptosis inhibitors
TargetsUpdating
Therapy Area/IndicationsStrokeAcquired Immunodeficiency Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRyan Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRyan Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsStrokeAcquired Immunodeficiency Syndrome

Other Information

ATC CodeN/A
Related LinksN/A